Pet Drug Reports

Drugs by active ingredient › Ivermectin + Praziquantel

Drug · combination of 2 active ingredients

Ivermectin + Praziquantel: adverse event reports

All products with this ingredient combination · 3 FDA-approved applications in the Green Book

3,382reports naming this combination, 2003–20260.3% of all reports · about 149 a year
47reports, 12 months to March 202656 in the 12 months before
55.8%classed serious, as reportedof 1,173 reports stating it
3.3%record death or euthanasia, as reported111 reports
78%of reports concern horses14.4% of all horse reports

Between July 2003 and March 2026 FDA received 3,382 adverse event reports listing a drug with the combination ivermectin and praziquantel as the recorded active ingredients. The Green Book lists 3 FDA-approved applications with exactly this combination.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient combination across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 47 reports named it, down 16% from 56 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 149 reports a year and 0.3% of all 1,357,245 reports (14.4% of all horse reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The signs named most often are application site swelling (24.4%), lip oedema (23.7%) and hypersalivation (10.5%). A report can list several signs, so shares add to more than 100%; 716 different terms appear across these reports. Application site swelling appears in 24.4% of these reports, a larger share than in the pooled reports for every drug containing praziquantel (1%).

78% of reports concern horses. Not every report describes illness: 13.7% as product or packaging defects. Of reports that state seriousness, 55.8% were classed as serious, and 3.3% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog16 · peak 3
Nov 2021: 1Feb 2022: 1May 2022: 3Aug 2022: 1Jan 2023: 2Nov 2024: 1Mar 2025: 1Sep 2025: 2Oct 2025: 1Nov 2025: 2Mar 2026: 12022202320242025
Cat0 · peak 1
2022202320242025
Horse209 · peak 11
Apr 2021: 3May 2021: 2Jun 2021: 3Jul 2021: 5Aug 2021: 9Sep 2021: 4Oct 2021: 5Nov 2021: 8Dec 2021: 3Jan 2022: 4Feb 2022: 2Mar 2022: 2Apr 2022: 6May 2022: 3Jul 2022: 5Sep 2022: 4Oct 2022: 3Nov 2022: 2Dec 2022: 3Feb 2023: 4Mar 2023: 1Apr 2023: 1May 2023: 8Jun 2023: 1Jul 2023: 9Aug 2023: 3Sep 2023: 4Oct 2023: 7Nov 2023: 6Dec 2023: 5Jan 2024: 1Feb 2024: 2Mar 2024: 2Apr 2024: 3May 2024: 4Jun 2024: 3Jul 2024: 5Sep 2024: 4Oct 2024: 7Nov 2024: 6Dec 2024: 5Jan 2025: 1Feb 2025: 2Mar 2025: 3Apr 2025: 6May 2025: 2Jun 2025: 1Jul 2025: 4Aug 2025: 2Sep 2025: 1Oct 2025: 11Nov 2025: 4Dec 2025: 1Jan 2026: 1Mar 2026: 32022202320242025
Other35 · peak 3
Apr 2021: 1Jun 2021: 1Oct 2021: 2Jan 2022: 1Mar 2022: 2Apr 2022: 1Aug 2022: 1Oct 2022: 1Nov 2022: 1Dec 2022: 1Jan 2023: 2May 2023: 2Jul 2023: 1Nov 2023: 1Dec 2023: 1May 2024: 1Jun 2024: 1Jul 2024: 1Aug 2024: 2Sep 2024: 2Oct 2024: 1Dec 2024: 3Apr 2025: 1May 2025: 1Sep 2025: 1Oct 2025: 1Jan 2026: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

01382752003: 18220032004: 2752005: 22520052006: 2592007: 23120072008: 2322009: 17620092010: 1812011: 15920112012: 1292013: 18320132014: 1652015: 22420152016: 1852017: 10720172018: 742019: 6120192020: 612021: 6020212022: 472023: 5820232024: 542025: 4820252026: 6

2026 covers reports received through March 2026 only.

Signs listed in reports

share of ivermectin + praziquantel reports listing the termall drugs containing praziquantelall horse reports

  1. Application site swelling[swelling where the product was applied]24.4%824
  2. Lip oedema23.7%802
  3. Hypersalivation[drooling]10.5%354
  4. Anorexia[not eating]6.5%219
  5. Anaphylactoid reaction[sudden allergic-type reaction]5.1%172
  6. Depression[dull, quiet or withdrawn]4.8%161
  7. Stomatitis4.4%148
  8. Application site erythema[reddened skin where the product was applied]4.3%146
  9. Tubes, Leaking[a product quality report, not a sign in an animal]3.9%132
  10. Diarrhoea[diarrhea]3.8%127
  11. Ataxia[unsteady, uncoordinated movement]3.7%125
  12. Facial oedema[swollen face]3.5%119
  13. Application site lesion[lesion where the product was applied]3.1%106
  14. Buccal irritation3.1%106
  15. Oral swelling3%100
  16. Accidental exposure[exposure that was not intended]2.9%99
  17. Drooling2.9%99
  18. Recumbency[lying down and unable or unwilling to rise]2.6%89
  19. Application site inflammation[inflammation where the product was applied]2.5%86
  20. Uncoded sign[a sign with no matching dictionary term]2.4%81
  21. Behavioural disorder NOS[behaviour change, type not specified]2.3%77
  22. Anaphylaxis[sudden severe allergic-type reaction]2.2%74
  23. Application site oedema[oedema where the product was applied]2.1%72

Top 30 of 716 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal15.4%521
Recovered with Sequela0.1%3
Ongoing2.7%90
Died3%100
Euthanized0.3%11
Outcome Unknown17.9%606

What kind of report it was

Safety issue85%2,876
Lack of expected effectiveness1.1%38
Both safety and lack of expected effectiveness0.1%4
Manufacturing or product defect13.7%464
Other0%0

Coloured bar: reports naming ivermectin + praziquantel. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Horse78%2,638
Dog6%204
Human exposure1.2%42
Donkey0.7%25
Cat0.3%10
Goat0.1%5

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year3.6%121
1 to 3 years5.7%192
4 to 7 years9.9%334
8 to 11 years11.2%378
12 years and over32.6%1,103
Age not given37.1%1,254

Weight of the animal

Under 5 kg (11 lb)1.4%48
5 to 9.9 kg (11–22 lb)1%35
10 to 24.9 kg (22–55 lb)1.6%53
25 to 44.9 kg (55–99 lb)1.4%47
45 kg and over (99 lb+)52.2%1,765
Weight not given42.4%1,434

Route of administration stated in reports: oral (2,842), topical (14), other (6), ophthalmic (2), intramuscular (1), subcutaneous (1).

In context

MeasureIvermectin + PraziquantelAll drugs containing praziquantelAll horse reportsAll reports
Reports3,38283,30318,3821,357,245
Share of that pool's reports naming this drug—4.1%14.4%0.3%
Classed serious, of reports stating it55.8%24.4%44.1%38.6%
Death or euthanasia recorded, per 1,000 reports32.83213663.8
Filed as lack of expected effectiveness (wholly or partly)1.2%——23%
Top term, share of reportsApplication site swelling 24.4%1%4.6%—

The praziquantel pool is every report naming praziquantel alone or in any combination; this combination accounts for 4.1% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Ivermectin + Pyrantel Pamoate161,6434,876
Milbemycin Oxime + Praziquantel33,1162,477
Ivermectin20,072286
Ivermectin + Praziquantel + Pyrantel Pamoate8,999100
Febantel + Praziquantel + Pyrantel Pamoate7,061415
Lufenuron + Milbemycin Oxime + Praziquantel6,704761
Emodepside + Praziquantel6,109175
Praziquantel + Pyrantel Pamoate5,037206
Praziquantel3,960336
Lufenuron + Praziquantel3,5261
Eprinomectin + Esafoxolaner + Praziquantel3,1931,105
Lotilaner + Moxidectin + Praziquantel + Pyrantel Pamoate2,2612,231

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing this combination (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
Zimecterin Gold PasteIvermectin, PraziquantelBoehringer Ingelheim Animal Health USA, Inc.HorsesNADA 141-214
EquimaxIvermectin, PraziquantelVirbac AH, Inc.HorsesNADA 141-215
Duocareapproval voluntarily withdrawnIvermectin, PraziquantelBoehringer Ingelheim Animal Health USA Inc.HorsesNADA 141-421

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about ivermectin + praziquantel reports

How many adverse event reports has FDA received for the combination ivermectin and praziquantel?

3,382 reports record a drug with the combination ivermectin and praziquantel as its active ingredients in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 47 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 3 approved applications with this combination; the reference list on this page names them without any counts.

What signs are reported most often?

application site swelling (24.4%), lip oedema (23.7%), hypersalivation (10.5%), swollen mouth (8.9%) and tongue oedema (6.9%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

horse (78%), dog (6%) and human exposure (1.2%). Among single-breed animals the most frequent labels are Quarter Horse, Thoroughbred, Arab and Paint; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

47 reports in the 12 months to March 2026, down 16% from 56 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that ivermectin + praziquantel harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of ivermectin + praziquantel?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.